Neurocrine Biosciences, Inc. (NBIX) announced positive results on Tuesday from its Phase 2 SAVITRI trial, which evaluated the effectiveness and safety of NBI-1065845 in adult patients with major depressive disorder or MDD.
The company confirmed that the trial met its primary and secondary goals, showing that the oral administration of NBI-1065845 once daily led to a significant improvement in the Montgomery Åsberg Depression Rating Scale total score compared to baseline at both Day 28 (primary) and Day 56 (secondary).
Neurocrine also noted that NBI-1065845 was generally well tolerated, with adverse events reported for both NBI-1065845 doses being similar to those observed in the placebo group.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.